Revenue
2017
2018
2019
2020
2021
2022
2023
2024
2025
Catheter Precision, Inc. (VTAK)
Price—Loading quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $819,000 | $420,000 | $442,000 | $14,000 | $22,000 | $259,000 | $7.2M | $6.3M | $5.9M |
| Gross profit | $756,000 | $378,000 | $412,000 | −$147,000 | −$1.5M | −$1.9M | −$1.7M | $2.1M | $1.7M |
| Gross margin | 92.31% | 90.00% | 93.21% | −1,050.00% | −6,990.91% | −738.61% | −22.93% | 32.78% | 29.05% |
| Research & development | $862,000 | $272,000 | $475,000 | $6.4M | $12.3M | $9.0M | $4.5M | $2.8M | $4.5M |
| Operating expenses | $21.9M | $11.6M | $78.5M | $26.8M | $27.7M | $33.5M | $56.1M | $33.2M | $19.5M |
| Operating income | −$21.1M | −$11.2M | −$78.1M | −$27.0M | −$29.3M | −$35.4M | −$57.7M | −$31.2M | −$17.8M |
| Operating margin | −2,581.56% | −2,676.90% | −17,673.98% | −192,578.57% | −133,027.27% | −13,668.34% | −801.92% | −498.00% | −302.56% |
| EBITDA | −$19.0M | −$9.1M | −$76.0M | −$26.5M | −$27.7M | −$33.0M | −$56.0M | −$30.5M | −$17.5M |
| EBITDA margin | −2,323.32% | −2,174.76% | −17,204.52% | −189,571.43% | −125,913.64% | −12,755.21% | −777.61% | −488.03% | −298.84% |
| Net income | −$17.2M | −$16.6M | −$70.6M | −$26.9M | −$25.1M | −$36.0M | −$57.0M | −$30.8M | −$17.8M |
| Net profit margin | −2,098.05% | −3,962.62% | −15,966.52% | −191,892.86% | −113,954.55% | −13,916.99% | −791.18% | −492.76% | −302.64% |
| Basic EPSper basic share | -$15.90 | -$126.91 | -$2,467.72 | -$4,936.20 | -$47,161.80 | -$201,590.00 | -$1,028,660.00 | -$793,250.00 | -$558,125.00 |
| Diluted EPSper diluted share | -$15.90 | -$126.91 | -$2,467.72 | -$4,936.20 | -$47,161.80 | -$201,590.00 | -$1,028,660.00 | -$793,250.00 | -$558,125.00 |
Owners
Reported shareholders
≈7.35%of listed shares
Jenkins Family Charitable Institute265.23K shares · Aug 30, 2024
View holders
| Holder | % owned |
|---|---|
Jenkins Family Charitable Institute | ≈7.35%265.23K shares |
JENKINS DAVID A | ≈1.34%48.49K shares |
Virtu Financial LLC | 0.55%19.86K shares |
UBS Group AG | 0.47%17.06K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.33%11.98K shares |
Tower Research Capital LLC (TRC) | 0.26%9.45K shares |
OSAIC HOLDINGS, INC. | 0.24%8.54K shares |
Allworth Financial LP | <0.01%300 shares |
COLOMBATTO MARTIN J | ≈<0.01%57 shares |
Caruso James Joseph | ≈<0.01%50 shares |
CITIGROUP INC | <0.01%22 shares |
Purpose Unlimited Inc. | <0.01%13 shares |
HARBOUR INVESTMENTS, INC. | <0.01%8 shares |
SBI Securities Co., Ltd. | <0.01%5 shares |
Percentages use 3.61M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 3 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jan 29, 2025Form 4 | COLOMBATTO MARTIN JDirector | SellCommon Stock · indirect | 3 | $0.40 | $1.20 | 0 |